Skip to site menu Skip to page content

Daily Newsletter

19 October 2023

Daily Newsletter

19 October 2023

Cardiac care start-up Ventricle nets $8m in seed funding

Ventricle Health's care model aims to reduce the average annual cost of heart failure care by 30-50%.

October 18 2023

Ventricle Health, a virtual cardiac care provider, has secured $8m in seed financing to expand its heart failure management therapeutic model in association with value-based care groups and payers.

This round was led by RA Capital Management, which was joined by other investors including Waterline Ventures.

The company’s care model focuses on established guideline-directed medical therapy (GDMT) pathways, offering patients the convenience of cardiology care appointments from their homes in three days.

Ventricle Health's home-based and virtually enabled care model aims to reduce the average annual cost of heart failure care by 30-50%.

Its leadership team is said to include heart failure clinicians, value-based care operators, and digital health innovators.

The start-up is currently operational, providing virtual and home-based clinical services to support accountable care organisations (ACOs), primary care practices, and payer partners in the Mid-Atlantic, Texas, Ohio, and Florida, with plans to expand into more markets.

Ventricle Health founder Dr. Daniel Bensimhon said: “Our foundational service lines offer a rapid path for either payers or value-based provider groups to connect heart failure patients to high quality cardiology services and provides a model for cardiologists to effectively manage more patients.

“Study after study has shown that getting heart failure patients on appropriate guideline-directed medical therapy can dramatically improve health outcomes and lead to marked reductions in costs and improvements in quality of life in just weeks – yet typically less than 20% of our patients are on these medications even when they come out of the hospital. Ventricle is here to change that.”

AI will become a key driver of medical device innovation

With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close